EMAIL THIS PAGE TO A FRIEND

Cell reports

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.


PMID 27264175

Abstract

Type I interferon (IFN), essential for spontaneous T cell priming against solid tumors, is generated through recognition of tumor DNA by STING. Interestingly, we observe that type I IFN is not elicited in animals with disseminated acute myeloid leukemia (AML). Further, survival of leukemia-bearing animals is not diminished in the absence of type I IFN signaling, suggesting that STING may not be triggered by AML. However, the STING agonist, DMXAA, induces expression of IFN-β and other inflammatory cytokines, promotes dendritic cell (DC) maturation, and results in the striking expansion of leukemia-specific T cells. Systemic DMXAA administration significantly extends survival in two AML models. The therapeutic effect of DMXAA is only partially dependent on host type I IFN signaling, suggesting that other cytokines are important. A synthetic cyclic dinucleotide that also activates human STING provided a similar anti-leukemic effect. These data demonstrate that STING is a promising immunotherapeutic target in AML.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML1957
ML RR-S2 CDA sodium salt, ≥95% (HPLC)
C20H24N10O10P2S2 · xNa+